# A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT02616640** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 114 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02616640
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-11
- **Primary completion:** 2018-11-23
- **Final completion:** 2024-07-30
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616640, "A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02616640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*